The peptide regulatory landscape is changing. The FDA initiated a review in early 2026 that is expected to reclassify several Category 2 peptides — including BPC-157 and TB-500 — back into the legal compounding framework, restoring access for physicians and patients who lost it under the 2023 enforcement actions. The legal status shown for each entry below reflects current April 2026 state. For the authoritative running update on which peptides are reclassified and when, see are peptides legal?.
How to read this catalog: Each entry includes a short description of mechanism, the current legal status (Category 1 = currently compoundable, Category 2 = currently restricted, Pending / Investigational = not yet approved), and a link to the full encyclopedia entry with mechanism detail, clinical evidence, and access pathways.
Growth hormone secretagogues
Compounds that stimulate the pituitary to release growth hormone pulsatilely, mimicking endogenous patterns.
GHRH analog that stimulates the pituitary to release endogenous growth hormone in natural pulses. The most accessible Category 1 GH-related peptide.
Combined GHRH analog (CJC-1295) and ghrelin mimetic (Ipamorelin) for amplified pulsatile GH release. Currently restricted from compounding.
Selective ghrelin receptor agonist that triggers GH release without significantly elevating cortisol or prolactin.
FDA-approved GHRH analog (Egrifta) for HIV-associated lipodystrophy. Used off-label for visceral fat reduction in metabolic medicine.
Healing & tissue repair
Peptides involved in soft-tissue recovery, angiogenesis, and skin health.
Synthetic pentadecapeptide derived from gastric juice, studied for tendon, ligament, and gastrointestinal healing in animal models.
Restricted; reclassification expected in 2026
Synthetic fragment of thymosin beta-4. Studied for muscle, tendon, and ligament repair through actin polymerization and angiogenesis.
Restricted; reclassification expected in 2026
Copper peptide complex with a long history in wound healing and cosmetic dermatology. Topical applications widely studied.
C-terminal tripeptide fragment of alpha-MSH studied for anti-inflammatory effects in inflammatory bowel disease and skin conditions.
Weight management
GLP-1 agonists, triple agonists, and metabolic peptides under active research for obesity and metabolic disease.
Eli Lilly's investigational triple agonist (GLP-1, GIP, glucagon). Phase 2 trial results showing ~24% weight loss at 48 weeks.
Investigational; not approved or available
Boehringer Ingelheim's investigational GLP-1 / glucagon dual agonist in Phase 3 trials for obesity and MASH (NASH).
Investigational; not approved or available
Eli Lilly's investigational oral non-peptide GLP-1 agonist. Early data suggests injectable-comparable weight loss without injections.
Investigational; not approved or available
Triple monoamine reuptake inhibitor (NDS) studied for obesity. Distinct mechanism from GLP-1 class.
Not FDA-approved in the US
Modified C-terminal fragment of human growth hormone studied for fat metabolism without affecting blood glucose or growth.
Selective NNMT inhibitor studied for fat mass reduction and metabolic benefits independent of caloric restriction.
Cognitive & neurological
Neuropeptides studied for focus, memory, anxiety modulation, and neuroprotection.
Russian-developed ACTH(4-10) analog studied for nootropic effects, BDNF expression, and stroke recovery.
Not FDA-approved in the US
Russian-developed peptide derived from tuftsin, studied for anxiolytic effects without sedation or dependence.
Not FDA-approved in the US
Porcine brain-derived peptide preparation used in Eastern Europe for stroke, dementia, and traumatic brain injury.
Not FDA-approved in the US
Angiotensin IV-derived peptide studied for synaptogenesis and HGF/c-Met pathway activation. Early-stage research.
Delta sleep-inducing peptide studied for sleep architecture modulation and stress response. Limited modern research.
Immune & longevity
Peptides involved in immune modulation, thymic function, and longevity-related pathways.
Synthetic peptide identical to a natural thymic peptide. FDA orphan drug status; widely used internationally for immune modulation.
Limited US compounding access
Russian-developed tetrapeptide studied for telomerase activation and pineal gland function. Limited rigorous human data.
Mitochondrial-derived peptide encoded in mitochondrial DNA. Studied for metabolic regulation and exercise mimetic effects.
Sexual wellness
Peptides that act on central pathways governing libido and sexual response.
Important context
Legal status changes. The peptide regulatory framework is genuinely fluid in 2026. The categories above reflect April 2026 state. Several restricted compounds are expected to return to Category 1 within months; conversely, additional enforcement actions could affect compounds currently available. The peptide legal status page is updated as regulatory developments occur.
Evidence quality varies. Some peptides have decades of human clinical trial data (Tesamorelin, PT-141). Others have promising mechanism studies and limited rigorous human evidence (BPC-157, MOTS-c). Some are derived primarily from Russian research that does not meet Western trial standards (Semax, Selank, Cerebrolysin, Epithalon). The encyclopedia entries flag evidence quality compound-by-compound rather than blurring it.
Access is physician-supervised.Therapeutic peptides for human use require a prescription from a licensed physician and preparation by a licensed compounding pharmacy. Grey- market “research chemical” sources are not safe access paths regardless of how they are marketed. See what happened to Peptide Sciences for context on the largest grey-market collapse and its aftermath.
Medical disclaimer
This encyclopedia is for informational purposes only and has not been clinically reviewed. It does not constitute medical advice. Always consult a licensed physician before considering any peptide therapy. Nuletic does not diagnose, treat, cure, or prevent any disease. Individual results vary. Meet our medical team.